Genmab — April 2020
-
Deres resultat er vel i denne omgang ikke noget helt vildt - de har vist at de får samme efffekt ved at behandle 5 dage som 10 dage. På pts, der allerede var hospitalsindlagte med symptomer på lungebetændelse uden behov for respirator. Godt halvdelen af disse pts kunne hjemsendes 14 dage efter deres deltagelse i studiet blev påbegyndt.
-
Men der er ingen sammenligninger med hvor mange af sådanne pts der blev hjemsendt uden samme behandling (eller en placebobehandling for den sags skyld), så man ved intet om hvor effektiv behandlingen er. De havde god bivirkningsprofil, ok. Det er fint. Men vi har et resultat, der viser at en vis procentdel af patienterne får det bedre efter at have være indlagt et stykke tid. Og det vifdste vi i forvejen. Vi er slet ikke i nærheden af en vaccine.
-
Der kommer mere - Gilead also said that a government-run clinical trial evaluating remdesivir in severely ill COVID-19 patients met the study's primary endpoint. That study is being conducted by the National Institute of Allergy and Infectious Diseases, which is expected to provide additional information about that trial end of May.
-
Tak Bulder.
-
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab https://www.nature.com/articles/s41375-020-0840-y
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind